科兴退市危机解除，来看看谁拿走了科兴640亿分红

Core Viewpoint - Sinovac Biotech Ltd. has resolved its delisting crisis and will continue to maintain its listing status on NASDAQ after undergoing a hearing process [1][23]. Group 1: Delisting Crisis - The delisting crisis began two months prior due to Sinovac's inability to provide its annual report for 2024, leading NASDAQ to issue a delisting notice on November 12, 2024 [3][25]. - The inability to provide the annual report stemmed from internal conflicts among shareholders, resulting in numerous lawsuits and a lack of cooperation from management [4][25]. - The departure of the company's auditor, due to the complicated situation, further hindered the ability to release the annual report, exacerbating the delisting crisis [5][25]. Group 2: Shareholder Conflicts - The shareholder disputes were primarily driven by financial interests [6][26]. - In 2025, after announcing a substantial dividend of $8.911 billion (approximately 640 million RMB), the conflicts among shareholders diminished significantly [7][26]. - The resolution of these conflicts allowed the company to continue its listing on NASDAQ [8][26]. Group 3: Shareholding Structure - Sinovac has a total share capital of approximately 71.86 million shares, with major shareholders including: - 1Globe Capital LLC: 25.77% (approximately 18,515,315 shares) [10][26]. - SAIF Advisors Ltd.: 15% (approximately 10,780,820 shares) [13][26]. - Wei Dong Yin: 8.85% (approximately 6,359,500 shares) [15][26]. - Vivo Capital LLC: 8.215% (approximately 5,903,000 shares) [17][26]. - Advantech Advisors (HK): 8.143% (approximately 5,851,423 shares) [18][26]. - The largest shareholder, 1Globe Capital, is associated with a group focused on international biotechnology and health technology research [10][26]. - The second-largest shareholder, SAIF Advisors, was originally known as SoftBank SAIF and is led by notable investor Yan Yan [13][26].